Covid PCR Test

Private Covid19 PCR Test

Covid19 PCR Test Price

£140

Turnaround Time

Next day results

Additional info

PCR testing can detect whether a person has an active (current) Covid-19 infection.

The assay
Nasal/Throat swabs showing a minimum sensitivity of 98% and a specificity of 100%.

The Lab
We use TDL (The London Laboratory).
This lab process is accredited by UKAS and is ISO 15189 compliant.

Covid Antigen Test Price

£80

Turnaround Time

10 minutes

Additional Information

Rapid test for the qualitative detection of SARS-CoV-2 antigen in a Nasal Swab.

CE marked

PERFORMANCE CHARACTERISTICS
Relative Sensitivity: 96.1% (95%CI*:91.2%-98.7%)* Relative Specificity: 99.0% (95%CI*:97.5%-99.7%)* Relative accuracy: 98.3% (95%CI*:96.9%-99.2%)*
* Confidence Intervals

Covid Antibody Test Price

£100

Turnaround Time

Next Day

Additional Information

Antibody testing can detect whether a person has been infected previously or has a vaccine-induced immune response.

Testing should be undertaken 14 days or more following exposure, onset of symptoms or post-vaccination. The incubation period of COVID-19 ranges from between 1 to 14 days, with the majority of cases manifesting with symptoms at 3–5 days.

Covid Vaccine Price

N/A

Availability

The COVID vaccine is only available through the NHS.

For further information visit the NHS coronavirus (COVID-19) vaccine webpage

Covid Vaccine

Not available

IT'S EASY AND SIMPLE

Cut down the development time with drag-and-drop website builder. Drop the blocks into the page, edit content inline and publish - no technical skills required.

IT'S EASY AND SIMPLE

Cut down the development time with drag-and-drop website builder. Drop the blocks into the page, edit content inline and publish - no technical skills required.

IT'S EASY AND SIMPLE

Cut down the development time with drag-and-drop website builder. Drop the blocks into the page, edit content inline and publish - no technical skills required.

TRENDY WEBSITE BLOCKS

Choose from the large selection pre-made blocks - full-screen intro, bootstrap carousel, slider, responsive image gallery with, parallax scrolling, sticky header and more.

TRENDY WEBSITE BLOCKS

Choose from the large selection pre-made blocks - full-screen intro, bootstrap carousel, slider, responsive image gallery with, parallax scrolling, sticky header and more.

TRENDY WEBSITE BLOCKS

Choose from the large selection pre-made blocks - full-screen intro, bootstrap carousel, slider, responsive image gallery with, parallax scrolling, sticky header and more.

Frequently Asked Questions

Covid19 PCR Test
The results and Fit to Travel certificate for PCR testing are available the next day.
Whilst every effort will be made, unfortunately we cannot offer a guarantee that the results will be back by a specific time, as the lab is a 3rd party business and we have no control over their schedule.

Having said that, so far this year our Lab has always been able to provide us with the results the next day. 100% success rate.

We will email you the results together with the fit to travel certificate.

Covid PCR test - SAMPLE RESULT
PCR Fit to Fly certificate - SAMPLE FIT TO FLY CERTIFICATE


Up to date guidance can be found for each destination, including entry requirements by visiting https://www.gov.uk/foreign-travel-advice.
It is your responsibility to ensure that you are fully aware of the COVID-19 requirements of the country or region you are travelling to.

Yes.
We use TDL (The London Laboratory).
This lab process is accredited by UKAS and is ISO 17025 compliant.

• This service is not suitable for anyone showing symptoms of COVID-19 or anyone who thinks they may have COVID-19. If you have any symptoms, please stay at home and follow UK government guidance

• Customers must bring their passport to the appointment to verify their identity, without this, the test will not be able to go ahead.

• If using this service to travel, the customer is responsible for checking the COVID-19 test requirements in accordance with the destination of travel.

• Whilst every effort will be made, we cannot guarantee results will be received the next day.
The lab is a 3rd party business and we have no control over their schedule.

• Due to the sensitivity of these tests, there is a very small chance the test result could be inconclusive. If your test result is inconclusive a full refund will be provided, and you will be invited to book another test within the time frame to suit you but this cannot be guaranteed. As you have been refunded for the first inconclusive test, you will be required to pay for the retest

• GP Matters will not be held liable for losses, costs, damage that you suffer or incur as a result of any delays in receiving the Covid19 test results or as a result of inconclusive test results

• GP Matters will also not be liable to you for any losses, costs or damages that you suffer or incur as a result of receiving a positive Covid19 test result (including, if you are unable to travel as a result of testing positive)

P|CR Test Glasgow

COVID-19 (SARS-CoV-2) PCR assay

Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus – Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) – which was first recognised in Wuhan, Hubei Province, China, in December 2019. Genetic sequencing of the virus suggests that SARS-CoV-2 is a betacoronavirus closely linked to SARS coronavirus.

Infectivity is now recognized to occur before the onset of symptoms and yet high titres of virus can be detected on upper airway surfaces in people who do not develop symptoms.

Infection with SARS-CoV-2, an RNA virus, is diagnosed using reverse-transcriptase PCR. The assays used at TDL show a minimum sensitivity of 98% and a specificity of 100%, with no cross-reactivity with other viruses.

Indications

The majority of people with COVID-19 have uncomplicated or mild illness (81%), with non-specific symptoms such as fever, fatigue, cough (with or without sputum production), anorexia, malaise, muscle pain, sore throat, dyspnea, nasal congestion, or headache. Rarely, patients may also present with diarrhoea, nausea and vomiting. Loss of taste and smell has been reported early in the infection.

A relatively small proportion of people, particularly but by no means exclusively in those aged >70 years, will develop severe illness requiring oxygen therapy (14%) and approximately 5% will require intensive care unit treatment. Time from the onset of the infection to hospitalisation can be up to ~13 days. Of those critically ill, most will require mechanical ventilation. The most common diagnosis in severe COVID-19 patients is severe pneumonia; this can progress to acute respiratory distress syndrome, and life-threatening multi-organ dysfunction and death. Mortality has been estimated at between 1 and 2% of those infected, the higher figure in men.


Limitations and clinical interpretation

As with all viral PCR assays, patients with very low viral loads are less likely to be detected. Negative (or ‘NOT detected’) results do not preclude infection with the SARS- CoV-2 virus and should not be the sole basis of a patient treatment/management or public health decision. Where there is a strong clinical suspicion of an early COVID-19 infection repeat sampling should be considered 24-48 hours later.

Patients with COVID-19 symptoms in intensive care have been shown to no longer carry the virus in the upper respiratory tract. Viral detection tests should assist in the decision on when to discontinue additional precautions for hospitalised patients. Results should be interpreted by a trained professional in conjunction with the patient’s history and clinical signs and symptoms, and epidemiological risk factors.

Detection of viral RNA by PCR does not equate with infectivity, unless infectious virus particles have been confirmed through virus isolation and cultured from the particular samples. Viral load can, however, be a potentially useful marker for assessing disease severity and prognosis: a study indicated that viral loads in severe cases were up to 60 times higher than in mild cases. 

Current PCR assays are able to detect all known SARS CoV-2 variants to date.


COVID-19: Diagnosis by PCR testing

Standard confirmation of acute SARS-CoV-2 infections is based on the detection of unique viral sequences by nucleic acid amplification tests (NAATs), such as real-time reverse-transcription polymerase chain reaction (RT-PCR). The assays’ targets include regions of the E, RdRP, N and S genes. PCR is the current “Gold Standard” test for the detection of SARS-Cov-2. 

Using nasal/throat swabs, samples are collected from symptomatic patients between days 1-5 from onset of symptoms. Respiratory secretions may be quite variable in composition, however, and the adequacy of sampling efforts may also vary. This can occasionally result in negative PCR results. In patients for whom SARS-CoV-2 infection is strongly suspected and upper respiratory tract swabs are negative, viral RNA may be detected in lower respiratory tract secretions, such as sputum or bronchoalveolar lavage. 

Detection of viral RNA by PCR may not equate with infectivity. Infectious virus particles have been detected using cell culture systems but the relationship between the infectivity of a sample and the contagiousness of the patient is unclear. Viral load can, however, be a potentially useful marker for assessing disease severity and prognosis: a study indicated that viral loads in severe cases were up to 60 times higher than in mild cases. 

Lateral flow devices for the detection of SARS-CoV-2 antigen in respiratory samples have been developed and are being used for large scale testing. These have limited value due to their ease of use, but they have significantly reduced sensitivity compared to PCR and the quality control is deficient with a high test failure rate. 

References

European Centre for Disease Prevention and Control. Coronavirus: Infection. Accessed 6 October 2020.

Grant P, et al. Extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase capacity for national testing programmes during a pandemic. BioXriv 8 April 2020.

Wölfel R, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020 May;581(7809):465-469. doi: 10.1038/s41586-020-2196-x. Epub 2020 Apr 1. PMID: 32235945.

Preliminary report from the Joint PHE Porton Down & University of Oxford. SARS-CoV-2 test development and validation cell: Rapid evaluation of Lateral Flow Viral Antigen detection devices (LFDs) for mass community testing. 

© Copyright 2021 GP Matters Limited - All Rights Reserved